Clinical trialNCT02846376TerminatedPhase 1Interventional

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

SponsorHackensack Meridian HealthEnrollment8Acute Myeloid Leukemia and Myelodysplastic Syndrome

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to determine the safety and benefit of nivolumab, ipilimumab or the combination of nivolumab with ipilimumab given after bone marrow transplant for patients with acute myelogenous leukemia and myelodysplastic syndrome.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Andrew Pecora, MD
Hackensack UMC
Principal Investigator
clinicaltrials.gov ↗
James McCloskey, MD
Hackensack UMC
Principal Investigator
clinicaltrials.gov ↗
Jamie Koprivnikar, MD
Hackensack UMC
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ipilimumab →Nivolumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Mar 2019
Primary completion: 21 Dec 2023
Completion: 21 Dec 2023
Last update posted: 18 Nov 2024
Registered enrollment: 8
Registry id: NCT02846376

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.